• 5040 Corporate Plaza Drive, Suite 7R, Colorado Springs, CO 80919
  • 719-347-5400
  • info@realmofcaring.org
  • 719-347-5400
  • info@realmofcaring.org
  • Home
  • Research
    • Research Library
    • Participate in Research
    • Observational Research Registry (ORR)
  • Resources
    • Aspen Green Giveaway
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
      • Client Additional Questions
    • Healthcare Portal
      • Practitioner Introduction
      • Cannabinoid Info
      • Practitioner Education Series
    • Blog
    • Find a Provider
    • Printable Resources
    • F.A.Q.
    • Best Practices
    • Glossary
  • About
    • What We Do
    • Who We Serve
    • Financials
    • Our Team
    • Supported Brands
    • Our Sponsors
  • Contact Us
Menu
  • Home
  • Research
    • Research Library
    • Participate in Research
    • Observational Research Registry (ORR)
  • Resources
    • Aspen Green Giveaway
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
      • Client Additional Questions
    • Healthcare Portal
      • Practitioner Introduction
      • Cannabinoid Info
      • Practitioner Education Series
    • Blog
    • Find a Provider
    • Printable Resources
    • F.A.Q.
    • Best Practices
    • Glossary
  • About
    • What We Do
    • Who We Serve
    • Financials
    • Our Team
    • Supported Brands
    • Our Sponsors
  • Contact Us
  • Donate
  • Register
  • Login
  • Home
  • Research
    • Research Library
    • Participate in Research
    • Observational Research Registry (ORR)
  • Resources
    • Aspen Green Giveaway
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
      • Client Additional Questions
    • Healthcare Portal
      • Practitioner Introduction
      • Cannabinoid Info
      • Practitioner Education Series
    • Blog
    • Find a Provider
    • Printable Resources
    • F.A.Q.
    • Best Practices
    • Glossary
  • About
    • What We Do
    • Who We Serve
    • Financials
    • Our Team
    • Supported Brands
    • Our Sponsors
  • Contact Us
Menu
  • Home
  • Research
    • Research Library
    • Participate in Research
    • Observational Research Registry (ORR)
  • Resources
    • Aspen Green Giveaway
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
      • Client Additional Questions
    • Healthcare Portal
      • Practitioner Introduction
      • Cannabinoid Info
      • Practitioner Education Series
    • Blog
    • Find a Provider
    • Printable Resources
    • F.A.Q.
    • Best Practices
    • Glossary
  • About
    • What We Do
    • Who We Serve
    • Financials
    • Our Team
    • Supported Brands
    • Our Sponsors
  • Contact Us
  • Register
  • Login
  • cannabinoid therapy, Cannabis, health, Medical marijuana, medicinal cannabis, quality of life
Loading...

A Cross-Sectional and Prospective Comparison of Medicinal Cannabis Users and Controls on Self-Reported Health

Introduction. Despite widespread legalization, the impact of medicinal cannabis use on patient level health and quality of life has not been carefully evaluated. The objective of this study was to characterize self-reported demographics, health characteristics, quality of life, and health care utilization of Cannabis Users compared with Controls. Methods. A longitudinal, cross-sectional web-based survey study was completed between April 2016 and February 2018. Study participants (N=1276) were a convenience sample of either patients with a diagnosed health condition or caregivers of a patient with a diagnosed health condition registered with the Realm of Caring Foundation (a nonprofit organization dedicated to therapeutic cannabis research and...
Read More

Carliner et al (2017) – Cannabis use, attitudes, and legal status in the U.S.: A review

Cannabis is widely used among adolescents and adults. In the U.S., marijuana laws have been changing, and Americans increasingly favor legalizing cannabis for medical and recreational uses. While some can use cannabis without harm, others experience adverse consequences. The objective of this review is to summarize information on the legal status of cannabis, perceptions regarding cannabis, prevalence and time trends in use and related adverse consequences, and evidence on the relationship of state medical (MML) and recreational (RML) marijuana laws to use and attitudes. Twenty-nine states now have MMLs, and eight of these have RMLs. Since the early 2000s, adult and adolescent perception of...
Read More

Treat et al. (2017). Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients

Objective: Oral cannabis extracts (OCEs) are being used in the treatment of epilepsy with increasing rates in the United States following product legalization; however, no studies demonstrate clear efficacy. We evaluated the duration of use of OCEs as a measure of perceived benefit in a cohort of patients with pediatric epilepsy. Methods: Retrospective chart review was performed of children and adolescents who were given OCEs for treatment of epilepsy. Results: Of the 119 patients included in the analysis, 71% terminated use of their OCE product during the study period. The average length of use of OCE was 11.7 months (range 0.3–57 months). Perceived seizure...
Read More

Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders

To present a summary of current scientific evidence about the cannabinoid, cannabidiol (CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders. We summarize the presentations from a conference in which invited participants reviewed relevant aspects of the physiology, mechanisms of action, pharmacology, and data from studies with animal models and human subjects. Cannabis has been used to treat disease since ancient times. D9 -Tetrahydrocannabinol (D9 -THC) is the major psychoactive ingredient and CBD is the major nonpsychoactive ingredient in cannabis. Cannabis and D9 -THC are anticonvulsant in most animal models but can be proconvulsant in some healthy animals. The psychotropic...
Read More

Cannabinoids and Cystic Fibrosis: A Novel Approach to Etiology and Therapy

Cannabis stimulates appetite and food intake. This property has been exploited to benefit AIDS and cancer patients suffering from wasting disease, by administering the whole plant or its major active ingredient ∆9-tetrahydrocannabinol (THC). Endogenous cannabinoids (“endocannabinoids”) are found in maternal milk. We have recently shown that endocannabinoids are critical for milk ingestion and survival of newborns because blocking CB1 receptors resulted in death from malnutrition. Lack of appetite resulting in malnutrition is a contributing factor to mortality in many Cystic Fibrosis (CF) patients. It is proposed here for the first time, to administer THC to CF patients. It is hoped that the cannabinoid will...
Read More

Cannabinoids for pediatric epilepsy? Up in smoke or real science?

Public interest in the use of “medical marijuana” for the treatment of childhood epilepsy has burgeoned in the last few years. This has occurred in parallel with a growing interest in “medical marijuana” in general. Physicians and pediatricians must balance their patients’ desire for immediate access to these products with the tenets of evidence-based medicine. This review discusses the biochemistry of cannabis products (the phytocannabinoids) setting this in the context of the endogenous endocannabinoid system. The differing and potentially modulating effects of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are reviewed. The evidence-base supporting or not the use of cannabis products for the treatment of neurological...
Read More

Clinical Endocannabinoid Deficiency (CECD): Can this Concept Explain Therapeutic Benefits of Cannabis in Migraine, Fibromyalgia, Irritable Bowel Syndrome and other Treatment-Resistant Conditions?

OBJECTIVES: This study examines the concept of clinical endocannabinoid deficiency (CECD), and the prospect that it could underlie the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome, and other functional conditions alleviated by clinical cannabis. METHODS: Available literature was reviewed, and literature searches pursued via the National Library of Medicine database and other resources. RESULTS: Migraine has numerous relationships to endocannabinoid function. Anandamide (AEA) potentiates 5-HT1A and inhibits 5-HT2A receptors supporting therapeutic efficacy in acute and preventive migraine treatment. Cannabinoids also demonstrate dopamine-blocking and anti-inflammatory effects. AEA is tonically active in the periaqueductal gray matter, a migraine generator. THC modulates glutamatergic neurotransmission via NMDA receptors....
Read More

Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It’s Been . . .

Background.—The use of cannabis, or marijuana, for medicinal purposes is deeply rooted though history, dating back to ancient times. It once held a prominent position in the history of medicine, recommended by many eminent physicians for numerous diseases, particularly headache and migraine. Through the decades, this plant has taken a fascinating journey from a legal and frequently prescribed status to illegal, driven by political and social factors rather than by science. However, with an abundance of growing support for its multitude of medicinal uses, the misguided stigma of cannabis is fading, and there has been a dramatic push for legalizing medicinal cannabis and research....
Read More

Future of Cannabis and Cannabinoids in Therapeutics

This study reviews human clinical experience to date with several synthetic cannabinoids, including nabilone, levonantradol, ajulemic acid (CT3), dexanabinol (HU-211), HU-308, and SR141716 (Rimonabant®). Additionally, the concept of “clinical endogenous cannabinoid deficiency” is explored as a possible factor in migraine, idiopathic bowel disease, fibromyalgia and other clinical pain states. The concept of analgesic synergy of cannabinoids and opioids is addressed. A cannabinoid-mediated improvement in night vision at the retinal level is discussed, as well as its potential application to treatment of retinitis pigmentosa and other conditions. Additionally noted is the role of cannabinoid treatment in neuroprotection and its application to closed head injury, cerebrovascular...
Read More

Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010

Opioid analgesic overdose mortality continues to rise in the United States, driven by increases in prescribing for chronic pain. Because chronic pain is a major indication for medical cannabis, laws that establish access to medical cannabis may change overdose mortality related to opioid analgesics in states that have enacted them. Medical cannabis laws are associated with significantly lower state-level opioid overdose mortality rates. Further investigation is required to determine how medical cannabis laws may interact with policies aimed at preventing opioid analgesic overdose.
Read More

REGISTER WITH THE RoC TODAY!

Realm of Caring focuses on research, education, building community, and improving quality of life. We are an educational resource for consumers, physicians, scientists, governments and the media.
Register now
  • 5040 Corporate Plaza Drive, Suite 7R, Colorado Springs, CO 80919
  • 719-347-5400
  • info@realmofcaring.org

RESEARCH

  • Observational Research Registry
  • Research Library
  • Participate in Research

EDUCATION

  • Client Portal
  • For Pets
  • Client Education Series
  • Glossary

COMMUNITY

  • Share Your Story
  • Volunteer
  • Internships

SUPPORTED BRANDS

  • Aspen Green
  • Charlotte’s Web
  • Elixinol
  • Stanley Brothers™
  • Stratos

Copyright © 2021 / Realm of Caring Foundation, Inc

  • Privacy
  • Disclaimer